id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-0085-0051,FDA,FDA-2017-D-0085,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2023-02-14T05:00:00Z,2023,2,2023-02-14T05:00:00Z,,2023-02-14T15:00:41Z,2023-03073,0,0,090000648569352e
FDA-2017-D-0085-0044,FDA,FDA-2017-D-0085,Best Practices for Convening a GRAS Panel; Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-22T05:00:00Z,2022,12,2022-12-22T05:00:00Z,,2022-12-22T14:39:30Z,2022-27714,0,0,090000648554882e
FDA-2017-D-0085-0045,FDA,FDA-2017-D-0085,Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance,Other,Guidance,2022-12-21T05:00:00Z,2022,12,2022-12-21T05:00:00Z,,2024-11-12T23:49:43Z,,1,0,0900006485549dab
FDA-2017-D-0085-0048,FDA,FDA-2017-D-0085,Reference-30-GRAS Notices Search Results Common Use In Food - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance,Supporting & Related Material,Background Material,2022-12-21T05:00:00Z,2022,12,,,2022-12-21T21:13:51Z,,0,0,0900006485549f5d
FDA-2017-D-0085-0046,FDA,FDA-2017-D-0085,Final Guidance - Reference List - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance,Supporting & Related Material,Background Material,2022-12-21T05:00:00Z,2022,12,,,2022-12-21T21:13:02Z,,0,0,09000064855494a0
FDA-2017-D-0085-0047,FDA,FDA-2017-D-0085,"Reference-29-Memorandum-November 4, 2010-Linda Kahl - Substances that Are Generally Recognized as Safe (GRAS); Experience with GRAS Notices - Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance",Supporting & Related Material,Background Material,2022-12-21T05:00:00Z,2022,12,,,2022-12-21T21:13:35Z,,0,0,09000064855494a1
FDA-2017-D-0085-0049,FDA,FDA-2017-D-0085,Reference-31-OECD 2017-Guidance on Grouping of Chemicals- Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance,Supporting & Related Material,Background Material,2022-12-21T05:00:00Z,2022,12,,,2022-12-21T21:14:18Z,,0,0,0900006485549f5e
FDA-2017-D-0085-0050,FDA,FDA-2017-D-0085,Reference-32-Ball 2016-Toward Good Read-Across Practice (GRAP) Guidance- Re: Best Practices for Convening a GRAS Panel: Guidance for Industry - Final Guidance,Supporting & Related Material,Background Material,2022-12-21T05:00:00Z,2022,12,,,2022-12-21T21:14:43Z,,0,0,0900006485549f5f
FDA-2017-D-0085-0042,FDA,FDA-2017-D-0085,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substances Generally Recognized as Safe: Best Practices for Convening a Generally
Recognized as Safe Panel",Notice,30 Day Proposed Information Collection,2022-10-27T04:00:00Z,2022,10,2022-10-27T04:00:00Z,2022-11-29T04:59:59Z,2022-12-21T16:18:56Z,2022-23378,0,0,0900006485462764
FDA-2017-D-0085-0017,FDA,FDA-2017-D-0085,Reference-16-Milch-2009-From-individual-preference-construction-group-decisions-framing-effects-group-processes re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:27Z,,0,0,0900006482cb21a1
FDA-2017-D-0085-0023,FDA,FDA-2017-D-0085,Reference-23-About-FEMA-GRAS-Program re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:58Z,,0,0,0900006482cb21aa
FDA-2017-D-0085-0028,FDA,FDA-2017-D-0085,Reference-28-Pew-2013-Draft-COI-Guidance-Consideration-FDA re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:58:20Z,,0,0,0900006482cb21af
FDA-2017-D-0085-0003,FDA,FDA-2017-D-0085,GUIDANCE -REFERENCE LIST  re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:17Z,,0,0,0900006482cb1e6f
FDA-2017-D-0085-0018,FDA,FDA-2017-D-0085,Reference-17-Jonas-2001-Confirmation-bias-sequential-information-search-after-preliminary-decisions re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:32Z,,0,0,0900006482cb21a2
FDA-2017-D-0085-0026,FDA,FDA-2017-D-0085,Reference-26-Guyatt-2010-Vexing-problem-guidelines-conflicts-interest-potential-solution re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:58:11Z,,0,0,0900006482cb21ad
FDA-2017-D-0085-0025,FDA,FDA-2017-D-0085,Reference-25-Norris-2011-Conflict-interest-clinical-practice-guideline-development-systematic-review re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:58:07Z,,0,0,0900006482cb21ac
FDA-2017-D-0085-0011,FDA,FDA-2017-D-0085,Reference-10-IOM-2009-Conflict-Interest-Medical-Research-Education-Practice re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:58Z,,0,0,0900006482cb219b
FDA-2017-D-0085-0016,FDA,FDA-2017-D-0085,Reference-15-Cheng-Chiou-2008-Framing-effects-group-investment-decision-making-role-group-polarization re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:22Z,,0,0,0900006482cb21a0
FDA-2017-D-0085-0019,FDA,FDA-2017-D-0085,Reference-18- Mancuso-2014-Effects-cognitive-biases-distributed-team-decision-making re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:37Z,,0,0,0900006482cb21a3
FDA-2017-D-0085-0024,FDA,FDA-2017-D-0085,Reference-24-Alpert-2004-ACCF-AHA-Codes-Conduct-Human-Studies-Research re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:58:03Z,,0,0,0900006482cb21ab
FDA-2017-D-0085-0021,FDA,FDA-2017-D-0085,Reference-20-FDA-2016-Draft-Guidance-Procedures-Evaluating-Appearance-Issues-FDA-Advisory-Committees re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:49Z,,0,0,0900006482cb21a8
FDA-2017-D-0085-0007,FDA,FDA-2017-D-0085,Reference-06-Croskerry-2002-Achieving-quality-clinical-decision-making-cognitive-strategies-detection-bias re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:40Z,,0,0,0900006482cb1e73
FDA-2017-D-0085-0005,FDA,FDA-2017-D-0085,Reference-02-Guidance-Frequently-Asked-Questions-About-GRAS re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:28Z,,0,0,0900006482cb1e71
FDA-2017-D-0085-0012,FDA,FDA-2017-D-0085,Reference-11 NAS-2013-Policy-Committee-Composition-Balance-Conflicts-Interest re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:03Z,,0,0,0900006482cb219c
FDA-2017-D-0085-0006,FDA,FDA-2017-D-0085,Reference-03-Report-Congressional-Requestors-Food-Safety-FDA-Should-Strengthen-Oversight-GRAS-Ingredients re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:35Z,,0,0,0900006482cb1e72
FDA-2017-D-0085-0009,FDA,FDA-2017-D-0085,Reference-08-Bazerman-2002-Why-good-accountants-do-bad-audits re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:49Z,,0,0,0900006482cb1e75
FDA-2017-D-0085-0027,FDA,FDA-2017-D-0085,Reference-27-NCCN-2014-NCCN-Disclosure-Policies-Potential-Conflicts-Interest re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:58:16Z,,0,0,0900006482cb21ae
FDA-2017-D-0085-0022,FDA,FDA-2017-D-0085,Reference-21-FDA-2014-Guidance-Public-Availability-Advisory-Committee-Members-Financial-Interest-Information-Waivers re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:54Z,,0,0,0900006482cb21a9
FDA-2017-D-0085-0014,FDA,FDA-2017-D-0085,Reference-13-van-Ginkel-van-Knippenberg-2012-Group-leadership-shared-task-representations-decision-making-groups re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:13Z,,0,0,0900006482cb219e
FDA-2017-D-0085-0013,FDA,FDA-2017-D-0085,Reference-12-Pagliari-2001-Potential-influence-small-group-processes-guideline-development re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:07Z,,0,0,0900006482cb219d
FDA-2017-D-0085-0004,FDA,FDA-2017-D-0085,Reference-01-Guidance-Regulatory-Framework-GRAS-Substances re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:22Z,,0,0,0900006482cb1e70
FDA-2017-D-0085-0010,FDA,FDA-2017-D-0085,Reference-09-Moore-2010-Conflict-of-interest-intrusion-bias re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:53Z,,0,0,0900006482cb219a
FDA-2017-D-0085-0008,FDA,FDA-2017-D-0085,Reference-07-Arnott-2006-Cognitive-biases-decision-support-systems-development re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:56:45Z,,0,0,0900006482cb1e74
FDA-2017-D-0085-0015,FDA,FDA-2017-D-0085,Reference-14-Tschan-2009-Explicit-reasoning-confirmation-bias-illusory-transactive-memory re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:18Z,,0,0,0900006482cb219f
FDA-2017-D-0085-0020,FDA,FDA-2017-D-0085,Reference- 19-FDA-2008-Guidance-Procedures-Determining-Conflict-Interest-Eligibility-Participation-FDA-Advisory-Committees re Best Practices for Convening a GRAS Panel: Guidance for Industry Draft Guidance,Supporting & Related Material,Background Material,2017-11-27T05:00:00Z,2017,11,,,2017-11-27T21:57:44Z,,0,0,0900006482cb21a7
FDA-2017-D-0085-0001,FDA,FDA-2017-D-0085,Guidance: Best Practices for Convening a Generally Recognized as Safe Panel,Notice,Notice of Availability,2017-11-16T05:00:00Z,2017,11,2017-11-16T05:00:00Z,2018-05-16T03:59:59Z,2018-02-08T02:03:44Z,2017-24845,0,0,0900006482c83776
FDA-2017-D-0085-0002,FDA,FDA-2017-D-0085,Best Practices for Convening a GRAS Panel: Guidance for Industry; Draft Guidance,Other,Guidance,2017-11-16T05:00:00Z,2017,11,2017-11-16T05:00:00Z,,2022-12-21T16:44:12Z,,0,0,0900006482c84b3d